Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Five months after Novartis paid $9.7bn for the RNAi project’s maker, Blackstone has put down a $1bn bet on a partial royalty interest.
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's…
Incremental data revealed at the conference could give Mirati, Exelixis and Seattle Genetics renewed hope.
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.